We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




European Partnership to Promote Development of Anticancer Cell Therapy Products

By LabMedica International staff writers
Posted on 19 Jul 2015
Print article
A leading European contract manufacturing organization is teaming up with a start-up biotech company to promote the clinical development of two unique anticancer cell therapy products.

PharmaCell BV (Maastricht, the Netherlands) is a leading European-based contract manufacturing organization in the area of cell therapy and regenerative medicine. PharmaCell has experience in supporting Phase I through Phase III clinical trials and early commercial manufacturing of cell therapy products.

PharmaCell is located in the center of Europe and operates two state-of-the-art GMP (good manufacturing practices)-licensed facilities with combined area of more than 4,500 square meters for growth of human cells and tissues.

CiMaas (Maastricht, the Netherlands) is a biotech startup spin-off of Maastricht University (the Netherlands) focused on the development of immune cell therapy for cancer patients. The company’s lead products are a dendritic cell vaccine that is ready to be validated and tested in clinical trials and natural killer (NK) cells obtained from healthy donors that have already proven in rodent studies to demonstrate great antitumor activity.

PharamaCell and CiMaas have agreed to collaborate on the clinical development of CiMaas’ products. Under the agreement, PharmaCell will provide consulting services for the writing of GMP-compliant documents for the purpose of translating CiMaas' cell therapy processes into GMP compatible clinical products. Options have been taken on a full technology transfer trajectory to be started and executed at a later date. A continuation option on a Phase I and possibly a Phase II clinical trial is also part of the agreement.

Dr. Wilfred Germeraad, CSO of CiMaas, said, “It is a wonderful opportunity to work together and it will immediately speed-up our work in translating the lab procedures into clinical products ready to be tested in patients with cancer.”

Alexander Vos, CEO of PharmaCell BV, said, “The CiMaas team has shown to be successful in bringing their technology to the point of preparing the initiation of clinical studies. We are excited to support them to make their production process GMP-compliant and help clear the path to bring their innovative therapies to benefit patients.”

Related Links:

PharmaCell BV
CiMaas
Maastricht University


Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Automated Blood Typing System
IH-500 NEXT
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test
New
Gold Member
Syphilis Screening Test
VDRL Antigen MR

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.